查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198127

前列腺癌診斷和治療市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Prostate Cancer Diagnostics and Therapy Market - Growth, Trends, and Forecast (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 124 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，前列腺癌診斷和治療市場預計將以約 13.7% 的複合年增長率增長。

由於診斷程序和外科手術的暫停，突然出現的 COVID-19 感染影響了癌症診斷和治療護理。 此外，許多研究表明，癌症患者，尤其是前列腺癌患者，由於其惡性腫瘤和化療引起的免疫抑制狀況，比未患癌症的人更容易感染冠狀病毒。我在這裡。 因此，首要建議是居家休息，避免非緊急診治。 根據美國國際癌症控制聯盟 (UICC) 2020 年 5 月的數據，美國的癌症診斷率在大流行期間顯著下降。 癌症診斷的這種下降預計將導致大流行期間需求的短期下降。 然而，放寬嚴格的規定有望重新開放前列腺癌診斷診所和研究活動，這有望促進大流行後時期的市場增長。

人口老齡化和前列腺癌的高患病率是推動所研究市場增長的主要因素。 根據 Globocan 2020，前列腺癌是男性中第二常見的癌症類型。 同一來源發布的數據顯示，前列腺癌的患病率為 1,414,259，佔全世界所有癌症患者的 7.3%。 由於前列腺癌在老年人中更為常見，預計全球人口老齡化也將推動市場增長。 例如，根據聯合國公佈的《2022年世界人口展望》，世界65歲及以上人口的比例預計將從2022年的10%上升到2050年的16%。 預計在預測期內，易患前列腺癌的老齡化人口的增加將推動市場增長。

此外，不斷增加的產品批准和開發預計將有助於所研究市場的增長。 例如，2022 年 3 月，美國食品和藥物管理局批准Novartis的 Pluvicto（櫓 Lu 177）用於治療患有特定類型晚期癌症的成年患者，該癌症稱為前列腺特異性膜抗原陽性轉移性去勢抵抗性前列腺癌。 vipivotide tetraxetan)。 因此，這些將導致前列腺癌藥物的採用增加，並將推動市場增長。

因此，預計市場將在上述所有因素的推動下保持高速增長。 然而，前列腺癌藥物的高價格和低臨床試驗成功率預計會阻礙市場增長。

前列腺癌診療市場趨勢

經直腸超聲 (TRUS) 細分市場預計在預測期內快速增長

預計在預測期內，經直腸超聲將佔據很大的市場份額。 經直腸超聲 (TRUS) 引導的活檢也是前列腺癌的常見診斷程序之一，仍然被認為是一種可行的選擇。 這是大多數泌尿科醫生都熟悉的技術，尿瀦留的風險低，並且對捐獻者來說快速方便。 對觀察前列腺的異常部位、大小、形狀非常有用。 在某些情況下，TRUS 被認為是一種可行的選擇，作為早期檢測前列腺癌的重要替代方法。 對於因幽閉恐懼症、金屬植入物或保險範圍而無法接受 MRI 程序的患者，TRUS 是具有臨床益處的良好選擇，從而有助於研究領域的發展。

此外，2022 年 2 月發表在《泌尿外科雜誌》上的一項研究發現，TRUS 活檢呈陰性的男性，尤其是前列腺特異性抗原 (PSA) 為 10 或以下的男性，更有可能死於前列腺癌-特定死亡率。已知極低。 出於這個原因，廣泛使用 MRI 靶向進行初始前列腺活檢非常令人擔憂，我們建議 MRI 靶向應僅限於活檢陰性後 PSA 為 10 ng/ml 或更高的男性。我在這裡. 這將推動採用經直腸超聲檢測前列腺癌，推動這一領域的增長。

此外，不斷增加的產品發布預計將有助於所研究細分市場的增長。 例如，2021 年 5 月，RSIP Vision 推出了一種新的前列腺 MRI 到超聲配準工具，該工具使用標準 MRI 掃描和經直腸超聲圖像提供 MRI 到超聲配準。。 由於在前列腺癌檢測中越來越多地採用經直腸超聲，此類先進的解決方案將進一步推動這一領域的增長。

在某些情況下，患者通常患有相關疾病，而 TRUS 活檢與其他程序相比具有顯著優勢。 因此，TRUS 廣為人知並被接受。 現在正在出現幾種新的圖像處理方法，並且預計在預測期內該領域的增長將加速。

預計在預測期內北美將保持重要的市場份額

由於前列腺癌患病率上升、意識提高和該地區研發增加等因素，預計北美將佔據很大的市場份額。 據美國癌症協會估計，到 2022 年，美國將發現並報告 268,490 例新的前列腺癌病例。 根據同一數據，每 10 名男性中就有 6 人在 65 歲以上被診斷出患有該病，而在 40 歲以下的男性中則很少見。 診斷時男性的平均年齡約為 66 歲。 前列腺癌的這種發病率預計將有助於該地區的市場增長。

美國食品和藥物管理局正在採取措施批准臨床階段的藥物並加速臨床開發，以推動癌症治療市場的增長。 公司和研究機構正在投資研發，為市場的增長做出貢獻。

前列腺癌患病率上升為市場參與者提供了重要機會。 主要市場參與者正在集中精力進行研發，以將新的可靠療法推向市場。 例如，在 2021 年 9 月，美國食品和藥物管理局將允許檢查身體組織的醫療專業人員（病理學家）作為輔助審查來自前列腺活檢（從身體移除的組織）的數字掃描幻燈片的許可軟件來幫助檢測區域疑似癌症。 預計這些努力將促進在美國引入診斷和治療前列腺癌，並成為市場增長的推動力。

北美市場參與者正在關注各種增長戰略，例如新產品發布、合作夥伴關係、兼併和收購。 例如，2021 年 9 月，Page 獲得了 USFDA 的批准，可以從頭營銷 PaigeProsate，這是一種用於前列腺癌檢測的臨床級 AI 解決方案。 同樣在 2021 年 1 月，Myovant 與Pfizer公司合作開始商業化 Orgovyx（relugolix），這是一種前列腺癌治療藥物，於 2020 年 12 月獲得批准。

因此，預計上述因素將在預測期內推動該地區的市場。

前列腺癌診斷和治療市場競爭對手分析

由於市場進入者眾多，前列腺癌診斷和治療市場競爭激烈。 全球前列腺癌診斷和治療市場包括幾家大型製藥和設備製造商，主要參與者主要位於特定產品市場。 市場上的主要參與者包括Abbott Laboratories、Astellas Corporation、AstraZeneca、Bayer Healthcare AG、Cellanyx Diagnostics Inc、Dendreon Corporation、Ferring Pharmaceuticals、Ipsen Group、Sanofi-Aventis、Tolmar Inc、GE Healthcare、Siemens Healthineers、F. Hoffmann - La Roche。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 老齡化社會和前列腺癌的高患病率
    • 藥物創新和基因組學/蛋白質組學開發
    • 提高政府對癌症認識的舉措
  • 市場製約因素
    • 前列腺癌藥物的高成本
    • 臨床試驗成功率低
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按類型
    • 良性前列腺增生症
    • 前列腺癌
    • 小細胞癌
    • 其他類型
  • 按方式
    • 診斷名稱
      • 組織活檢
      • 經直腸超聲檢查
      • 實驗室測試
      • 前列腺特異性抗原檢測
      • 尿檢
      • 影像診斷
    • 治療
      • 手術
      • 放射治療
      • 治療藥物
      • 激素療法
      • 化療
      • 其他治療
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Abbvie Inc.
    • Astellas Pharma Inc.
    • AstraZeneca PLC
    • Bayer AG
    • F. Hoffmann-La Roche Ltd
    • Ipsen SA
    • Johnson & Johnson Services Inc.
    • Koninklijke Philips NV
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi-Aventis
    • Thermo Fisher Scientific

第七章市場機會與未來趨勢

簡介目錄
Product Code: 47468

The prostate cancer diagnostics and therapy market was expected to register a CAGR of nearly 13.7% during the forecast period.

Cancer diagnosis and treatment care were impacted by the sudden emergence of COVID-19 infection due to the halt in diagnostic procedures and surgical procedures. Moreover, as per many studies, cancer patients, especially prostate cancer patients, are more susceptible to coronavirus than individuals without cancer, as they are in an immunosuppressive state caused by malignancy and anticancer treatment. Thus, they are majorly suggested to stay at home and avoid all non-emergent diagnoses and treatment. According to the Union for International Cancer Control (UICC) in May 2020, there is a significant decrease in cancer diagnostics rates in the United States during the pandemic. Such decreases in cancer diagnostics are expected to have a short-term decline in demand during the pandemic period. However, the relaxation of the strict regulations is expected to contribute to the reopening of diagnostic clinics and research activities for prostate cancer, thereby contributing to the growth of the market during the post-pandemic period.

The major factor attributing to the growth of the market studied is an aging population and a high prevalence rate of prostate cancer. According to Globocan 2020, prostate cancer is the second most common type of cancer in the male population. As per the data published by the same source, the prevalence of prostate cancer was found to be 1,414,259, or 7.3% of the total cancer cases worldwide. As prostate cancer is more common in the elderly population, the rising aging population in the world is also expected to propel market growth. For instance, according to the World Population Prospects 2022 published by the United Nations, the share of global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. Such an increase in the geriatric population who are prone to developing prostate cancer is expected to drive the growth of the market over the forecast period.

Furthermore, the rising product approvals and developments are expected to contribute to the growth of the studied market. For instance,in March 2022, the United States Food and Drug Administration approved Novartis's Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer. Therefore, these will lead to increased adoption of prostate cancer therapies, driving market growth.

Hence, owing to all the aforementioned factors, the market is anticipated to propel at high growth rates. However, the high cost of prostate cancer drugs and the low success rate of clinical trials are expected to hinder market growth.

Prostate Cancer Diagnostics & Therapy Market Trends

The Transrectal Ultrasound (TRUS) Segment is Expected to Grow at Rapid Pace Over the Forecast Period

Transrectal ultrasound is expected to hold a significant share of the market over the forecast period. The transrectal ultrasound (TRUS) guided biopsy is also among the common diagnostic procedures performed for prostate cancer, which is still considered a viable option. It is quick and convenient to the provider, with a familiar approach to most urologists and a low risk of urinary retention. It is very useful to observe the abnormal areas of the prostate, size, and shape of the prostate. TRUS is considered a viable option in some cases as an important alternative for the early detection of prostate cancer. For patients who cannot undergo MRI procedures due to claustrophobia, metal implants, or lack of insurance coverage, TRUS is a good option with clinical benefits, thereby contributing to the growth of the studied segment.

Furthermore, according to the study published in the Journal of Urology, in February 2022, men who have negative TRUS biopsies have an extremely low prostate cancer-specific death rate, especially if their prostate-specific antigen (PSA) is below 10. This raises major concerns regarding the widespread use of MRI-targeting for the first prostate biopsy and advises that MRI-targeting should be reserved for men whose PSA is greater than 10 ng/ml following a negative biopsy. This will lead to increased adoption of transrectal ultrasound for the detection of prostate cancers, thereby driving this segment's growth.

In addition, the rising product launches are expected to contribute to the growth of the studied segment. For instance, in May 2021, RSIP Vision launched a new prostate MRI-to-ultrasound registration tool that provides MRI-to-ultrasound registration using standard MRI scans and trans-rectal ultrasound images. Such advanced solutions will further drive this segment's growth due to the increased adoption of transrectal ultrasound diagnostics in the detection of prostate cancers.

In several cases, the patients often suffer from associated diseases, where the TRUS biopsy has a considerable edge over other procedures. Thus, it is widely known and accepted. At present, with several new approaches coming up with imaging, the growth of this segment is estimated to be rapid during the forecast period.

North America is Expected to Retain a Significant Market Share During the Forecast Period

North America is anticipated to hold a significant market share, owing to the factors such as the increasing prevalence of prostate cancer, coupled with the rising awareness and increasing research and development in this region. According to the American Cancer Society, in 2022, an estimated 268,490 new prostate cancer cases was identified were and reported in the United States. In addition according to the same source, about 6 cases in 10 are diagnosed in men who are 65 or older, and it is rare in men under 40. The average age of men at diagnosis is about 66. Such an incidence of prostate cancer is expected to contribute to the growth of the market in this region.

The United States Food and Drug Administration is taking steps to enhance the growth of the cancer therapy market by approving drugs, which are in the clinical phase, thus accelerating clinical developments. Companies and research organizations are investing in research and development (R&D), thereby contributing to the growth of the market.

The rising number of prostate cancer cases is creating huge opportunities for market players. The major market players are focusing on R&D activities to bring new and reliable treatments to the market. For instance, in September 2021, the United States Food and Drug Administration authorized the marketing of software to assist medical professionals who examine body tissues (pathologists) in the detection of areas that are suspicious for cancer as an adjunct (supplement) to the review of digitally-scanned slide images from prostate biopsies (tissue removed from the body). Such initiatives will lead to increased adoption of prostate cancer diagnosis and treatment in the United States, thereby driving market growth.

Market players in North America are focusing on various growth strategies such as new product launches, partnerships, mergers, and acquisitions. For instance, in September 2021, Paige received USFDA approval for the de novo marketing of PaigeProsate, a clinical-grade AI solution for prostate cancer detection. In addition, in January 2021, Myovant partnered with Pfizer to commercialize its prostate cancer drug Orgovyx (relugolix), approved in December 2020.

Therefore, owing to the above-mentioned factors, the market is expected to drive in this region over the forecast period.

Prostate Cancer Diagnostics & Therapy Market Competitor Analysis

The market for prostate cancer diagnostics and therapy is highly competitive due to the presence of a number of market players. Several large drug and equipment manufacturers exist within the global prostate cancer diagnostic and therapy market, and their status as major players lies primarily within specific product markets. Some of the key players in the market include Abbott Laboratories, Astellas Inc., AstraZeneca, Bayer HealthCare AG, Cellanyx Diagnostics Inc., Dendreon Corporation, Ferring Pharmaceuticals, Ipsen Group, Sanofi-Aventis, Tolmar Inc, GE Healthcare, Siemens Healthineers, and F. Hoffmann-La Roche AG.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Aging Population and High Prevalence Rate of Prostate Cancer
    • 4.2.2 Innovation in Drugs and Developments in Genomics and Proteomics
    • 4.2.3 Increasing Government Initiatives for Cancer Awareness
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Prostate Cancer Drugs
    • 4.3.2 Low Success Rate of Clinical Trials
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Benign Prostatic Hyperplasia
    • 5.1.2 Prostatic Adenocarcinoma
    • 5.1.3 Small Cell Carcinoma
    • 5.1.4 Other Types
  • 5.2 By Modality
    • 5.2.1 Diagnosis
      • 5.2.1.1 Tissue Biopsy
      • 5.2.1.2 Transrectal Ultrasound
      • 5.2.1.3 Clinical Laboratory Examination
      • 5.2.1.3.1 Prostate-specific Antigen Testing
      • 5.2.1.3.2 Urine Testing
      • 5.2.1.4 Diagnostic Imaging
    • 5.2.2 Treatment
      • 5.2.2.1 Surgery
      • 5.2.2.2 Radiation Therapy
      • 5.2.2.3 Therapeutics
      • 5.2.2.3.1 Hormone Therapy
      • 5.2.2.3.2 Chemotherapy
      • 5.2.2.3.3 Other Treatments
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc.
    • 6.1.2 Astellas Pharma Inc.
    • 6.1.3 AstraZeneca PLC
    • 6.1.4 Bayer AG
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Ipsen SA
    • 6.1.7 Johnson & Johnson Services Inc.
    • 6.1.8 Koninklijke Philips NV
    • 6.1.9 Merck & Co. Inc.
    • 6.1.10 Pfizer Inc.
    • 6.1.11 Sanofi-Aventis
    • 6.1.12 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS